In the last trading session, 1.51 million Vir Biotechnology Inc (NASDAQ:VIR) shares changed hands as the company’s beta touched 1.19. With the company’s per share price at $4.73 changed hands at $0.09 or 1.94% during last session, the market valuation stood at $653.86M. VIR’s last price was a discount, traded about -205.5% off its 52-week high of $14.45. The share price had its 52-week low at $4.32, which suggests the last value was 8.67% up since then.
Analysts gave the Vir Biotechnology Inc (VIR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.56. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended VIR as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Vir Biotechnology Inc’s EPS for the current quarter is expected to be -0.74.
Vir Biotechnology Inc (NASDAQ:VIR) trade information
Instantly VIR was in green as seen at the end of in last trading. With action 0.64%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -35.56%, with the 5-day performance at 0.64% in the green. However, in the 30-day time frame, Vir Biotechnology Inc (NASDAQ:VIR) is -15.69% down.
The consensus price target for the stock as assigned by Wall Street analysts is 20, meaning bulls need an upside of 76.35% from its current market value. According to analyst projections, VIR’s forecast low is 20 with 20 as the target high. To hit the forecast high, the stock’s price needs a -322.83% plunge from its current level, while the stock would need to soar -322.83% for it to hit the projected low.
Vir Biotechnology Inc (VIR) estimates and forecasts
Year-over-year growth is forecast to reach -77.25% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 2.38M. 6 analysts are of the opinion that Vir Biotechnology Inc’s revenue for the current quarter will be 2.38M. The company’s revenue for the corresponding quarters a year ago was 3.08M and 2.38M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -22.48%. The estimates for the next quarter sales put growth at 0.15%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -18.74%. The 2025 estimates are for Vir Biotechnology Inc earnings to increase by 16.37%, but the outlook for the next 5-year period is at 10.19% per year.
VIR Dividends
Vir Biotechnology Inc is expected to release its next quarterly earnings report in June.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 12.0632% or 16.43 million shares worth $146.26 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 5.82 shares estimated at $27.52 million under it, the former controlled 4.21% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.49% of the shares, roughly 3.44 shares worth around $16.27 million.
